Our lead drug candidate, ENA-001, is a patent-protected new chemical entity (NCE) beginning pivotal clinical trials in the US.  With its novel mechanism-of-action and demonstrated safety and efficacy, it holds the potential to dramatically improve the lives of those impacted by several of the Nation’s Top Health Emergencies; including the Drug Overdose Epidemic and COVID-19 Pandemic. ENA-001 will offer new treatment options for physicians, emergency responders, and care-givers addressing respiratory depression in multiple settings.